TEVA$34.41
$34.4
Chart
Performance
Key Stats
AI TEVA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldTeva Pharmaceutical Industries Limited shows mixed signals. Fundamentally, it demonstrates resilience with consistent revenue and manageable debt, but profitability is volatile, and it currently carries a significant debt load. Thematic exposure to healthcare is positive, but specific growth drivers are not as pronounced as in tech-focused companies. Technical indicators suggest caution, with downward trends across multiple timeframes.
Thematic
Teva operates within the essential healthcare and pharmaceutical sector, benefiting from consistent demand. Its focus on generics and biopharmaceuticals positions it to capture growth in these segments. However, the sector faces regulatory pressures and intense competition, moderating its thematic appeal.
Fundamental
Teva's financials present a mixed picture. While revenue shows some stability and growth, profitability has been inconsistent, with recent quarters showing net losses. The company carries a substantial debt load, although its cash position is adequate. The dividend yield has been zero since late 2017.
Technical
Technical indicators for Teva are mixed. While some shorter-term oscillators suggest potential buying opportunities or consolidation, longer-term moving averages and momentum indicators lean towards a neutral to slightly bearish sentiment, indicating a lack of strong conviction in either direction.
| Factor | Score |
|---|---|
| Healthcare & Pharmaceuticals Demand | 80 |
| Generic Drug Market Growth | 75 |
| Biopharmaceutical Innovation | 70 |
| Regulatory Environment | 50 |
| Competition Intensity | 55 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 30 |
| Growth | 65 |
| Balance Sheet Health | 40 |
| Cash Flow | 70 |
| Dividends | 0 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 60 |
| Support & Resistance | 50 |
| Short-term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Potential Undervaluation
The P/S ratio of 1.2 is below the industry average of 1.5, suggesting the company might be undervalued relative to its revenue generation capabilities.
Positive EPS Surprises
The company has exceeded earnings per share (EPS) estimates in 8 out of the last 12 reported quarters, indicating consistent operational performance.
Bearish Points (7)
Negative Trailing Net Income
The Trailing Twelve Months (TTM) net income is negative (-$440 million), indicating a lack of profitability over the past year.
High Price-to-Sales Ratio
The TTM Price-to-Sales (P/S) ratio of 1.5 is higher than the previous year's 1.2, potentially indicating a more expensive valuation relative to revenue.
Calendar
November 2017
27
Ex-Dividend Date
December 2017
12
Next Dividend Date
July 2025
30
Next Earnings Date
H: $0.64
A: $0.62
L: $0.59
H: 4.32B
A: 4.28B
L: 4.20B
Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Seasonals
Price Target
23.34 USD
The 39 analysts offering 1 year price forecasts for TEVA have a max estimate of 30.00 and a min estimate of 18.07.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
A leading global generic and biosimilar pharmaceutical company, formed from the merger of Mylan and Pfizer's Upjohn business. Direct and significant competitor to Teva across many therapeutic areas and markets.
Weight: 90
Formerly Novartis's generics division, Sandoz is now an independent public company and a major global player in generic drugs and biosimilars, making it a primary competitor to Teva.
Weight: 88
A prominent Indian multinational pharmaceutical company with a substantial global presence in generic pharmaceuticals, biosimilars, and active pharmaceutical ingredients (APIs), directly competing with Teva.
Weight: 87
India's largest pharmaceutical company, with a strong focus on both generic and specialty pharmaceuticals globally, leading to direct competition with Teva in various markets and therapeutic segments.